Comparative Data Analysis and Ensartinib Approval
Key Themes:
- Matching-adjusted indirect comparisons (MAIC) of lorlatinib versus alectinib or brigatinib
- Overview of the eXalt3 study for ensartinib
- Implications of ensartinib’s December 2024 FDA approval
Notable Insights:
- Dr Dietrich analyzed insights from the MAIC of lorlatinib versus other ALK inhibitors
Dr Lovly provided an overview of the eXalt3 study following ensartinib’s recent FDA approval in December 2024
